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Abstract
Background: Association of genetic-variants in the FADS1-FADS2-gene-cluster with fatty-acid-composition in blood of adult-
populations is well established. We analyze this genetic-association in two children-cohort-studies. In addition, the
association between variants in the FADS-gene-cluster and blood-fatty-acid-composition with eczema was studied.
Methods and Principal Findings: Data of two population-based-birth-cohorts in the Netherlands and Germany (KOALA,
LISA) were pooled (n=879) and analyzed by (logistic) regression regarding the mutual influence of single-nucleotide-
polymorphisms (SNPs) in the FADS-gene-cluster (rs174545, rs174546, rs174556, rs174561, rs3834458), on polyunsaturated
fatty acids (PUFA) in blood and parent-reported eczema until the age of 2 years. All SNPs were highly significantly associated
with all PUFAs except for alpha-linolenic-acid and eicosapentaenoic-acid, also after correction for multiple-testing. All tested
SNPs showed associations with eczema in the LISA-study, but not in the KOALA-study. None of the PUFAs was significantly
associated with eczema neither in the pooled nor in the analyses stratified by study-cohort.
Conclusions and Significance: PUFA-composition in young children’s blood is under strong control of the FADS-gene-
cluster. Inconsistent results were found for a link between these genetic-variants with eczema. PUFA in blood was not
associated with eczema. Thus the hypothesis of an inflammatory-link between PUFA and eczema by the metabolic-pathway
of LC-PUFAs as precursors for inflammatory prostaglandins and leukotrienes could not be confirmed by these data.
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It has been well established that genetic variants in the fatty acid
desaturase genes (FADS1 and FADS2) associate with the fatty acid
composition in adult populations [1]. Several studies have shown
that the D-5 and the D-6 desaturase enzymes are involved in fatty
acid metabolism in adults and that these enzymes are genetically
regulated by variants of the FADS1 and FADS2 genes, respectively
[2–8].
Empirical and theoretical evidence exist that fatty acid
metabolism may be involved in atopic eczema [9–14]. Some
studies found, that dietary intake of certain fatty acids can
contribute to the development of allergic diseases. Kompauer et al
showed a positive association between hay fever and arachidonic
acid (AA) intake, and allergic sensitisation and oleic acid intake in
German adults [15].
Long chain polyunsaturated fatty acids (LC-PUFA) can
influence inflammatory responses, as they are precursors of
eicosanoids and docosanoids [16]. The link between PUFA and
inflammatory processes are the eicosanoids with arachidonic acid
(AA) as their main precursor. Eicosanoids derived from AA (e.g.
leukotrienes LTB4, prostaglandins PGE2, PGI2 or thromboxanes
TXA2) have mainly pro-inflammatory effects [16]. According to
findings of several studies a defect in enzyme activity of D-6
desaturase, encoded by the FADS2 gene, leads to enhanced blood
levels of the n-6 and n-3 parent fatty acids linoleic (LA) and alpha-
linolenic acid (ALA), respectively, and decreased levels of AA and
eicosapentaenoic acid (EPA), whereas docosahexaenoic acid
(DHA) levels are not influenced [5,6]. Schaeffer et al. showed
that the variability of serum fatty acid levels explained by genetic
variants in the FADS1 FADS2 gene cluster is highest for AA with
28% [6]. Thus, variants in the FADS1 FADS2 gene cluster may be
indirectly associated with inflammatory processes via their
influence on endogenous LC-PUFA production, particularly AA
production. Figure 1 show these metabolic pathways of n-6 and
n-3 fatty acids and pathways of production of pro-inflammatory
and less inflammatory eicosanoids and anti-inflammatory docosa-
noids schematically [12].
No study has empirically confirmed the genetic link between the
variants in the FADS1 FADS2 gene cluster with polyunsaturated
fatty acids (PUFA) in children. Schaeffer et al found an association
of rarer FADS haplotypes with a reduced eczema risk in adults [6],
but so far, no study has been published relating both genotypes and
fatty acids to eczema development in children. Therefore, we
analyzed this genetic association in a children cohort study pooled
from two population based birth cohorts and investigate the
Figure 1. Metabolic pathways of n-6 and and n-3 fatty acids. Dashed arrows indicate pathways absent in human mammals. Figure is based on
modified figures form Duchen et al. Glaser et al., and Park et al. [11,12,40]. LA=linoleic acid, GLA=gamma linolenic acid, DGLA=Dihomo-gamma-
linolenic acid, AA=arachidonoc acid, A=adrenic acid, ALA=alpha-limolenic acid, EPA,=eicospentaenoic acid, DPA=docosapentaenoic acid,
DHA=docosahexaenoic acid; LTs=leukotrienes, PGs=prostaglandins, TXs=thromboxanes, RVs=Resolvins.
doi:10.1371/journal.pone.0013261.g001
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acid composition and eczema up to the age of two years.
Methods
Ethics statement
Approval by the respective local Ethics Committees (Maastricht
University/University Hospital of Maastricht, Bavarian General
Medical Council) and written informed consent from participants’
families (parents) were obtained in both KOALA and LISA
studies.
Study design and population
The KOALA Birth Cohort Study (‘‘Kind, Ouders en gezondheid:
Aandacht voor Leefstijl en Aanleg’’) is a prospective cohort study of
2834 mother-infant pairs in the Netherlands. Aim of the KOALA
study was to investigate factors that influence the clinical
expression of atopic disease with a main focus on lifestyle factors
(e.g. anthroposophy, dietary habits, breastfeeding, intestinal micro
flora, and gene-environment-interactions). Enrollment started in
October 2000. Details of the study design have been described
elsewhere [17,18].
The LISA study (‘‘Influences of Lifestyle related Factors on the Immune
System and the Development of Allergies in Childhood’’) is an ongoing
population-based birth cohort study of unselected 3097 newborns.
The study was designed to assess ‘Influences of Lifestyle related
Factors on the Immune System and the Development of Allergies
in Childhood’. Between November 1997 and January 1999,
n=3097 healthy full-term newborns (gestational age$37 weeks)
were recruited from 14 obstetrical clinics in Munich (n=1467),
Leipzig (n=976), Wesel (n=306), and Bad Honnef (n=348).
Details on study design are published elsewhere [19,20].
The studied analysis population with information on genotypes,
fatty acids and eczema at 2 years of age comprised 546 children in
the KOALA birth cohort study and 333 in the LISA birth cohort
study.
For details on both studies (see Supporting Information
Appendix S1).
Fatty acid analysis
In the KOALA study blood was collected in EDTA-tubes
during a home visit to the child around age 2 years, by trained
nurses according to a standardized protocol. The EDTA-plasma
was used for the analysis of the fatty acid status and was, after
centrifugation, stored in cryovials at 280uC. The EDTA-plasma
was deproteinated and the precipitate was removed by centrifu-
gation. Then the sample was applied to an aminopropyl-solid-
phase column to selectively elute the phospholipid fraction
[21,22].
In the LISA study venous blood samples were collected in
serum-separator-tubes. Samples were centrifuged and serum was
frozen in plastic vials and stored at 280uC until analysis. The
analysis of plasma-glycerophospholipids composition was per-
formed by a sensitive and precise high-throughput method as
described recently [23].
For details (see Supporting Information Appendix S2).
Genotyping
In KOALA, genomic DNA was extracted from buccal swabs
using standard methods as described previously [24]. In LISA,
genomic DNA was extracted from EDTA blood.
Five variants of the FADS1 FADS2 gene cluster (rs174545,
rs174546, rs174556, rs174561, rs3834458) were typed with
MALDI-TOF-MS.
For details (see Supporting Information Appendix S3).
Determination of infants’ IgE
In the KOALA study total and specific IgE were determined at
age 1 (against hen’s eggs, cow’s milk, and peanuts) and 2 years
(against eggs, cow’s milk, peanut, birch pollen, grass pollen, cat, dog
and house-dust mite) by blood sampling during home visits [25–29].
In the LISA study blood samples were collected during physical
examination of the infant at age 2 years and analysed for total and
specific IgE using the RAST-CAP-FEIA-system (Pharmacia,
Freiburg, Germany) as previously described [30]. For details
(see Supporting Information Appendix S4).
Definition of outcome variable parental reported eczema
In both the KOALA and LISA study the definition of ‘‘parental
reported eczema’’ is based on the questionnaire-reported occur-
rence of ‘‘itchy rash that was coming and going’’ at any time
within the first two years of life [18,31].
For details (see Supporting Information Appendix S5).
Statistical analysis
Allele frequencies, Fisher’s exact test of Hardy-Weinberg-
Equilibrium (HWE), the linkage disequilibrium (LD) tests
Lewontin’s D’ and pairwise-squared correlations r
2 were calculat-
ed for the study population and for both studies separately.
Single SNP linear regression analyses for the relation between
FADS variants and the nine continuous outcome variables (fatty
acids) were conducted applying an additive coded model. P-Values
were corrected for multiple testing by Bonferroni correction.
Logistic regression was applied to evaluate the effect of each
single SNP and of each fatty acid separately on the dichotomous
coded outcome ‘‘parental reported eczema during the first two
years of life’’. No corrections for multiple testing were applied in
logistic regression.
All analyses were performed using the statistical software SAS,
version 9.1.3 [32,33], except calculation of linkage disequilibrium
measures (JLIN) [34].
For details (see Supporting Information Appendix S6).
Results
Study characteristics for both study populations separately and
combined are listed in Table 1.
There are some differences between both studies in the
percentages of boys, high maternal education, family history of
asthma or allergy, proportion of maternal smoking during
pregnancy and exclusive breastfeeding. Mean percentage contri-
butions of fatty acids to plasma phospholipids in the KOALA
cohort and to plasma glycerophospholipids in the LISA cohort are
similar, except for an almost twofold higher percentage value of
EPA in the KOALA study, which might be related to the different
population studied with a potentially higher fish consumption in
the Netherlands, as well as the different analytical method used.
Information regarding position, possible functional region and
genotyping frequencies for the five analyzed SNPs of the FADS1
FADS2 gene cluster (see Supporting Information Table S1).
Minimum P-value of Fisher’s exact test for violation of Hardy-
Weinberg-Equilibrium (HWE) for any of the five SNPs was 0.48
(rs174546) in the whole study population and 0.62 and 0.61 for the
KOALA and LISA study populations separately.
Lewontin’s D’ and pairwise-squared correlations r
2 for the
KOALA study and for the LISA study are depicted in Figure 2.
In the KOALA study Lewontin’s D’ ranged between 0.99 and 1.0
and the pairwise-squared correlations r
2 ranged between 0.89 and
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2
between 0.87 and 1.0. Both measures confirm that all five SNPs
are in high linkage disequilibrium (LD).
Single SNP associations with fatty acids
Mean levels and standard deviations for each fatty acid by
genotype of each SNP (rs174545, rs174546, rs174556, rs174561,
rs3834458) for the combined study population and for the
KOALA and LISA studies separately are listed in in the Online
Repository (see Supporting Information Table S2, Table
S3 and Table S4). Note that mean levels of GLA, ALA, EPA
and DHA are naturally logged means to account for the severely
skewed distributions of these fatty acids.
Single SNP regression analyses of each additive coded SNP
(0/1/2) with each fatty acid in the combined study population of
the KOALA and LISA studies at age 2 years revealed that all
SNPs are highly significantly associated with all fatty acids except
for ALA and EPA (natural log scale, Table 2). This is true even
though all P-values have been conservatively corrected for
multiple testing according to Bonferroni’s method. With respect
to ALA, corrected significance at the 5% level was only reached
for rs174545 and rs3834458 but not for the other SNPs.
Regarding EPA, regression coefficients were in the same
d i r e c t i o na n dt h es a m eo r d e ro fm a g n i t u d ea sf o rD P Aa n d
DHA, but corrected P-values were only between 0.05 and 0.09.
Separate analyses for both study populations revealed that in the
LISA study associations of the SNPs were significant only with
LA, GLA, DGLA, AA and EPA after correction for multiple
testing (see Supporting Information Table S5 and Table
S6). In the KOALA study all SNPs showed a significant
Table 1. Characteristics of study population.
KOALA-Study LISA-Study Total
n
mean
or % 95%-CI n
mean
or % 95%-CI n
mean or
% 95%-CI
% boys 546 50.4 (46.2–54.6) 333 55.6 (50.2–60.9) 879 52.3 (49.0–55.6)
% high maternal education 543 58.9 (54.8–63.1) 330 66.7 (61.6–71.8) 873 61.9 (58.6–65.1)
% parental asthma or allergy 546 57.0 (52.8–61.1) 332 68.7 (63.7–73.7) 878 61.4 (58.2–64.6)
%maternal smoking during pregnancy 546 3.1 (1.7–4.6) 330 10.3 (7.0–13.6) 876 5.8 (4.3–7.4)
% exclusively breastfed for at least 3 months 538 50.0 (45.8–54.2) 331 71.6 (66.7–76.5) 869 58.2 (54.9–61.5)
fatty acids (mean % wt of total FA)
Linoleic (LA) 546 21.37 (21.14–21.60) 333 22.22 (21.92–22.52) 879 21.69 (21.51–21.88)
c-Linolenic (GLA) 542 0.07 (0.07–0.08) 333 0.11 (0.10–0.11) 875 0.09 (0.08–0.09)
ln (GLA)
a 542 22.93 (23.00–22.85) 333 22.33 (22.37–22.29) 875 22.70 (22.75–22.65)
Dihomo-c-linolenic (DGLA) 546 2.82 (2.77–2.87) 333 2.91 (2.84–2.97) 879 2.85 (2.81–2.89)
Arachidonic (AA) 546 9.06 (8.95–9.16) 333 9.33 (9.19–9.47) 879 9.16 (9.08–9.25)
Adrenic (A) 545 0.47 (0.46–0.48) 333 0.40 (0.39–0.41) 878 0.44 (0.44–0.45)
a-Linolenic (ALA) 544 0.21 (0.21–0.22) 333 0.24 (0.23–0.25) 877 0.22 (0.22–0.23)
ln (ALA)
a 544 21.61 (21.64–21.58) 333 21.49 (21.52–21.45) 877 21.56 (21.59–21.54)
Eicosapentaenoic (EPA) 546 1.00 (0.98–1.03) 333 0.55 (0.52–0.58) 879 0.83 (0.81–0.86)
ln (EPA)
a 546 20.05 (20.09–20.02) 333 20.68 (20.72–20.63) 879 20.29 (20.32–20.26)
n-3 Docosapentaenoic (DPA) 546 0.92 (0.91–0.94) 333 0.97 (0.95–0.99) 879 0.94 (0.93–0.95)
Docosahexaenoic (DHA) 546 2.67 (2.61–2.74) 333 3.07 (2.99–3.15) 879 2.82 (2.77–2.88)
ln (DHA)
a 546 0.95 (0.93–0.97) 333 1.09 (1.07–1.12) 879 1.00 (0.99–1.02)
% parental reported eczema of child in first 2 years of life 542 30.6 (26.7–34.5) 333 14.1 (10.4–17.9) 875 24.3 (21.5–27.2)
IgE at 2 years of life
mean total IgE (IU/ml) 544 59.3 (34.9–83.7) 327 56.3 (44.3–68.3) 871 58.2 (42.3–74.0)
% specifc IgE (egg) 544 5.5 (3.6–7.4) 333 4.8 (2.5–7.1) 877 5.2 (3.8–6.7)
% specifc IgE (milk) 544 16.9 (13.8–20.1) 333 4.2 (2.0–6.4) 877 12.1 (9.9–14.2)
% specifc IgE (peanut) 544 5.0 (3.1–6.8) 333 1.2 (0.0–2.4) 877 3.5 (2.3–4.8)
% specifc IgE (birch)
b 535 0.4 (20.1–0.9) - - - - - -
% specifc IgE (gras)
b 538 1.9 (0.7–3.0) - - - - - -
% specifc IgE (cat) 543 2.8 (1.4–4.1) 333 0.6 (20.2–1.4) 876 1.9 (1.0–2.9)
% specifc IgE (dog)
c 543 2.6 (1.2–3.9) - - - - - -
% specifc IgE (dust mite) 544 6.8 (4.7–8.9) 333 0.6 (20.2–1.4) 877 4.7 (3.3–6.1)
aMean levels of GLA, ALA, EPA and DHA are naturally logged means to account for the severely skewed distributions of these fatty acids; see methods section.
bIn the LISA study % specific IgE for sensitization to birch and gras was not determined separately but for a mix of grass, trees and herbs only (0.9% (95%-CI 20.1–1.9))
at age 2.
cIn the LISA study % specific IgE for sensitization to dog was not determined at age 2.
doi:10.1371/journal.pone.0013261.t001
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regression coefficients of SNPs were in the same direction for all
PUFAs so the lack of significance regarding n-3 PUFA in the
LISA study may just reflect a loss of power due to the smaller
sample size of the LISA study compared to that of the KOALA
study.
Figure 2. Pairwise linkage disequilibrium measured by Lewontin’s D’ and r
2 for the common five single nucleotide polymorphisms
(SNP) in the KOALA (Panel A) and the LISA (Panel B) birth cohort studies.
doi:10.1371/journal.pone.0013261.g002
Table 2. Associations of the five analyzed variants in the FADS1 FADS 2 gene region with fatty acids.
Fatty acid LA GLA DGLA AA A ALA EPA DPA DHA
SNP C18_2n_6 ln(C18_3n_6) C20_3n_6 C20_4n_6 C22_4n_6 ln(C18_3n_3) ln(C20_5n_3) C22_5n_3 ln(C22_6n_3)
rs174545
P-value (corrected) 4.1E-10 1.3E-04 6.5E-13 5.4E-38 0.003 0.039 0.071 1.7E-05 3.2E-04
ß-coefficient 0.964 20.191 0.224 20.818 20.021 0.057 20.080 20.046 20.059
R
2 (explained var.) 5.3% 2.5% 6.7% 18.3% 1.8% 2.5% 1.2% 3.0% 3.3%
rs174546
P-value (corrected) 3.7E-10 7.9E-05 1.4E-12 2.9E-39 0.002 0.066 0.066 5.9E-06 1.5E-04
ß-coefficient 0.962 20.194 0.221 20.828 20.022 0.055 20.080 20.048 20.061
R
2 (explained var.) 5.3% 2.6% 6.5% 18.8% 2.0% 2.6% 1.2% 3.2% 2.5%
rs174556
P-value (corrected) 1.1E-09 0.002 2.3E-13 3.9E-37 0.009 0.218 0.054 1.4E-06 6.3E-05
ß-coefficient 0.975 20.170 0.235 20.836 20.021 0.050 20.085 20.052 20.065
R
2 (explained var.) 5.1% 1.9% 6.7% 17.9% 1.6% 1.9% 1.2% 3.5% 2.7%
rs174561
P-value (corrected) 1.2E-09 0.002 5.0E-13 2.1E-37 0.005 0.384 0.051 9.8E-07 6.3E-05
ß-coefficient 0.971 20.174 0.232 20.836 20.021 0.047 20.085 20.053 20.065
R
2 (explained var.) 5.0% 2.0% 6.7% 18.0% 1.7% 2.0% 1.2% 3.6% 2.7%
rs3834458
P-value (corrected) 3.9E-10 1.1E-04 3.8E-14 5.7E-38 0.005 0.018 0.092 5.9E-06 6.0E-05
ß-coefficient 0.970 20.193 0.236 20.823 20.019 0.061 20.079 20.049 20.064
R
2 (explained var.) 5.3% 2.6% 7.3% 18.3% 1.7% 2.6% 1.1% 3.2% 2.6%
Note: Corrected P-values to account for multiple testing are obtained by dividing not corrected P-values by 45 (5 single SNPanalyses of 9 outcomes); ß-coeffcient is the
respective regression estimate of the additive coded SNP (0/1/2) for the respective outcome (PUFA) in a simple regression model.
doi:10.1371/journal.pone.0013261.t002
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eczema
Of all analyzed indicator coded SNPs of the FADS1 FADS2 gene
cluster none showed a statistically significant association with the
dichotomous outcome parental reported eczema in the first 2 years
of life (Table 3) in both unadjusted and adjusted analyses (see
methods). Odds ratios (OR) for carriers of one or two minor alleles
in comparison to non-carriers range from 1.3 to 1.5 in unadjusted,
and 1.3 to 1.4 in adjusted analyses, respectively. However, 95%-
confidence limits always include the null-effect of an OR of 1.0.
Moreover, tests for multiplicative allelic trend (genotypes coded 0,
1, 2) also showed that none was significant at the 5% level with,
even though no correction for multiple testing was applied.
Separate analyses for both study populations revealed that in
the LISA-study all SNPs of the FADS1 FADS2 gene cluster showed
significant associations with the dichotomous outcome parental
reported eczema in the first 2 years of life in both unadjusted and
adjusted analyses, with ORs of about 2 and 4 for heterzygous and
homozygous minor allele carriers, which is in good agreement
with multiplicative increase of risks (confirmed by P-values for
multiplicative trend between 0.003 and 0.005 without correction
for multiple testing (see Supporting Information Table S7).
By contrast, no associations were found within the KOALA study,
where all ORs were between 0.9 and 1.2, whereas upper
boundaries of the 95% confidence intervals were below 2.0.
No significant association of any analyzed SNP of the FADS
gene with total IgE level or specific IgE at the age of one or two
years of the child could be established, neither in the KOALA nor
in the LISA study (results not presented).
Associations of fatty acids with parental reported eczema
No single PUFA was significantly associated with parental
reported eczema of the child in the first 2 years of life after
adjustment (see methods), neither in analyses of the combined
study population (Table 4), nor in separate analyses for the
KOALA and LISA studies (see Supporting Information
Table S8).
Discussion
This is the first study presenting associations between the
genetic variants in the FADS1 FADS2 gene cluster with fatty acid
composition in a population based sample of children.
We found that all five analyzed variants of the FADS1 FADS2
gene cluster are associated with polyunsaturated fatty acids LA,
GLA, DGLA, AA, A, ALA, EPA, DPA and DHA, in particular
with AA. Except for the n-3 fatty acids ALA and EPA these
associations are highly significant even after conservative Bonfer-
roni correction for multiple testing. For most PUFAs this is in line
with previous reports showing these associations in adult
populations [4–8]. However, in contrast to previous studies in
adults, all SNPs in the present study in children are also highly
significantly associated with DHA in one of the study populations
(KOALA study). In the same population, Molto ´ et al found a
relation between DHA in blood of the KOALA mothers during
pregnancy and the mothers’ FADS variants [35].
Our study confirms previous reports that carriers of the minor
alleles showed higher levels of n-6 precursor fatty acids LA, DGLA
and n-3 precursor fatty acids ALA and decreased product levels of
the n-6 fatty acids GLA, AA, A and n-3 fatty acids EPA, DPA and
DHA. Thus carriers of the minor alleles show enhanced desaturase
substrate levels (substrate accumulation) and decreased desaturase
product levels indicative of a lower desaturase activity, in
agreement with previous studies [5,6]. Thus, our results confirm
that the FADS1 FADS2 gene cluster modulates the PUFA
metabolism and demonstrate that this is also the case in children
at the age of 2 years. A functional basis for such a regulation was
recently shown by Lattka et al. in a study investigating the FADS2
Table 3. Association of FADS1 FADS 2 variants with parental reported eczema.
SNP n OR 95%-CI
P-value
Trend n OR 95%-CI P-value Trend
unadjusted adjusted
rs174545 C/C 399 1.00 - 0.07 392 1.00 - 0.13
C/G 364 1.32 0.95–1.85 357 1.32 0.94–1.87
G/G 93 1.43 0.86–2.39 92 1.34 0.79–2.28
rs174546 C/C 401 1.00 - 0.09 394 1.00 - 0.16
C/T 363 1.30 0.93–1.81 356 1.30 0.92–1.83
T/T 94 1.40 0.84–2.33 93 1.30 0.77–2.21
rs174556 C/C 424 1.00 - 0.05 417 1.00 - 0.12
C/T 358 1.34 0.96–1.86 351 1.33 0.95–1.87
T/T 76 1.49 0.86–2.58 75 1.33 0.75–2.35
rs174561 T/T 427 1.00 - 0.07 420 1.00 - 0.15
T/C 356 1.31 0.94–1.82 349 1.31 0.93–1.84
C/C 77 1.46 0.84–2.51 76 1.30 0.74–2.29
rs3834458 T/T 396 1.00 - 0.06 389 1.00 - 0.10
T/Z 370 1.28 0.92–1.79 363 1.28 0.91–1.81
Z/Z 91 1.54 0.93–2.57 90 1.42 0.84–2.42
Note: Odds ratios (OR) of indicator coded SNPs (reference is homozygous major alleles genotype) on eczema are estimated by logistic regression. Adjustment comprises
study cohort (indicator coded dummy variables: KOALA study conventional, KOALA study alternative recruitment group vs. LISA study as reference), sex, maternal
education, maternal smoking during pregnancy and exclusive breastfeeding for at least 3 months.
doi:10.1371/journal.pone.0013261.t003
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both SNPs are potential promoter polymorphisms and located in a
region important for transcription regulation. The minor alleles of
SNP rs968567, but not rs3834458 (studied also in our study),
showed a statistical significant increased effect on promoter activity
and binding activity to two protein complexes activating the
transcription factor ELK1 in that study. However, one of the rare
other functional studies on FADS2 found a decreased promoter
activity for rs3834458, suggesting the need for many more
functional studies [37].
A previous study in adults found protective associations of
carriers of minor alleles of the FADS1 FADS2 gene cluster with
allergic rhinitis and atopic eczema [6]. In our analyses we could
confirm such an association between FADS variants and eczema
only for the German study population, but clearly not within the
larger sample of children of the Netherlands. Whether these
inconsistent results suggest that in children less common variants
of the FADS1 FADS2 gene cluster are actually related to the
development of eczema within the first 2 years of life requires
further investigations with further independent study populations.
In contrast to some previous studies summarized in several
reviews [9–11], we found no evidence for a direct link between the
analyzed blood PUFA levels and eczema. This was true for analyses
based on the combined study population as well as for separate
analyses of the KOALA and LISA cohorts. Apparently, the
development of disease cannot be simplified to one underlying
pathway on fatty acid metabolism. On the other hand, larger
sample sizes and analyses in further study populations may be
necessary to draw any final conclusion on the role of fatty acid
composition in blood and eczema. Also, studies of gene-diet
interactions may be needed to resolve these inconsistencies, since
populations vary widely in the intake n-3PUFAs from fish products.
Strengths and Limitations
With data on variants of the FADS1 FADS2 gene cluster, PUFA
and information on eczema status within the first 2 years of life for
more than 800 children this is a large study despite the potential
lack of power to detect small effects regarding eczema.
Genotyping for both study populations (KOALA, LISA) were
done in the same lab at the Helmholtz Center Munich.
Fatty acids were derived from phospholipids in the KOALA
study and from serum glycerophospholipids in the LISA study and
analyzed at two different labs by somewhat different methods, but
we do not think that this compromised our results. Both labs
(Laboratory for Health Protection Research, National Institute for
Public Health and the Environment, Bilthoven, the Netherlands
and Division of Metabolic Diseases and Nutritional Medicine, Dr.
von Hauner Children’s Hospital, Ludwigs-Maximilians-University
of Munich) have a long lasting experience in fatty acid analysis.
Moreover, Glaser et al. have recently shown that fatty acid analysis
of serum glycerophospholipids by high throughput analysis results
in only minor deviations in values of fatty acids compared to
analysis of serum phospholipid fatty acids [23]. Indeed, the fatty
acid composition data was quite similar for both study populations,
except for EPA, which might reflect different dietary habits with
higher consumption levels of fish, which is the prime dietary
source of EPA, in the Netherlands than in Bavaria (cf. Table 1).
We used a similar definition of the outcome ‘‘parental reported
eczema of child within the first 2 years of life’’, but slightly different
wording of the questions and slightly different timing of
questionnaires, covering the entire first two years of life in the
two cohorts. Despite these similarities we found more than double
the percentage in parental reported eczema in the children of the
KOALA study (30.6%) than in the sample of the German LISA
study (14.1%), even though in KOALA parents the prevalence of
asthma and allergies was lower (57.0%) than in LISA parents
(68.7%). This raises the question of whether lifestyle differences are
responsible for the marked difference in % eczema in children in
the two cohorts. There are two additional elements which further
press this question: First, the FADS1 and FADS2 polymorphism
prevalence is remarkably similar in the two populations, suggesting
similar genetic background in the two populations. Second, in the
LISA study, 71% of children are exclusively breastfed vs. only
50% in the KOALA study. To compare, the reported prevalence
on eczema defined by symptoms in young children in two other
birth cohort studies are 25% in children of age 4 years in the
Netherlands and 16% for the first 2 years of life years in Germany
[38,39]. However, we do not think that any differences in eczema
between the LISA and KOALA study affected the results to an
appreciable extent, since we conducted, in addition to unadjusted
analyses, also analyses adjusted for study cohort. The higher
prevalence of eczema in KOALA could point to a higher
proportion of non-atopic eczema, and if the FADS effect would
be confined to atopic (IgE-mediated) eczema, it could have been
Table 4. Association of fatty acids with parental reported eczema.
Fatty Acid n OR 95%-CI P-value n OR 95%-CI P-value
unadjusted adjusted
LA C18_2n_6 875 0.99 0.94–1.05 0.85 860 1.03 0.97–1.09 0.39
GLA ln(C18_3n_6) 871 0.00 0.00–0.08 0.00 856 0.88 0.72–1.07 0.19
DGLA C20_3n_6 875 0.92 0.71–1.21 0.57 860 0.95 0.72–1.25 0.71
AA C20_4n_6 875 1.00 0.89–1.13 0.97 860 1.02 0.90–1.15 0.80
A C22_4n_6 874 3.41 0.82–14.16 0.09 859 0.85 0.17–4.15 0.84
ALA ln(C18_3n_3) 873 0.79 0.50–1.25 0.32 858 0.99 0.61–1.61 0.97
EPA ln(C20_5n_3) 875 1.53 1.09–2.15 0.01 860 0.82 0.55–1.21 0.31
DPA C22_5n_3 875 0.46 0.19–1.11 0.08 860 0.60 0.24–1.50 0.27
DHA ln(C22_6n_3) 875 0.87 0.48–1.59 0.66 860 1.53 0.80–2.95 0.20
Note: Odds ratios (OR) of measured PUFA on eczema are estimated by logistic regression. Adjustment comprises study cohort (indicator coded dummy variables:
KOALA study conventional, KOALA study alternative recruitment group vs. LISA study as reference), sex, maternal education, maternal smoking during pregnancy and
exclusive breastfeeding for at least 3 months.
doi:10.1371/journal.pone.0013261.t004
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absence of a FADS effect on total and specific IgE in both cohorts
makes this explanation unlikely.
At present we have no convincing explanation, why we found a
significant association between variants of the FADS gene and
eczema only in the German LISA study, but not in the
Netherland’s KOALA study. Since Molto ´ et al found that the
DHA deficit in the homozygous minor allele carriers could be
overcome by intake of fish at the recommended level of 2 portions
a week [35] we speculate that the difference between LISA and
KOALA may reflect a lower intake of n-3 long chain PUFAs in
LISA, as a consequence of which the genetic effect is manifest in
LISA but not in KOALA. Based on this, we recommend that
further studies are done in populations with low n-3 PUFA intake.
In conclusion, this is the first study that confirms in children of age
2 years the previously found associations of genetic variants in the
FADS1 FADS2 gene cluster with fatty acid composition in serum
phospholipids or glycerophospholipids and that also analyzed the
potential influence of FADS1 FADS2 genotypes and PUFAs to
eczema.
Variants of the FADS1 FADS2 gene cluster clearly do regulate
the metabolism of PUFA in young children. Inconsistent results
were found for a link between these genetic variants with eczema.
In the German LISA study all SNPs were significantly associated
with eczema. In the Netherland’s KOALA study this was clearly
not the case. In both study populations PUFA was not associated
with eczema. Thus the hypothesis of an inflammatory link between
PUFA and eczema by the metabolic pathway of LC-PUFAs as
precursors for inflammatory prostaglandins and leukotrienes could
not be confirmed by these data. This would suggest either that this
pathway is not or only marginally involved in eczema develop-
ment, that other risk factors for early childhood eczema may be
more important, or that eczema may have heterogeneous etiology
with only a small segment of the population susceptible for effects
of endogenous fatty acids metabolism or gene-diet-interaction; or a
combination of these arguments.
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